We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immediate Diagnosis Provided at POC for Cardiac Patients

By LabMedica International staff writers
Posted on 12 Oct 2009
A new biochip analyzer will help save cardiac patients lives by providing immediate diagnosis at the point of care (POC). More...
The technology is based on the concept of using a biochip as a reaction platform with multiple specific ligands (antibodies and antigens) attached at pre-defined sites on the surface.

The Evidence MultiStat biochip analyzer is a product of Randox (Crumlin, UK). In addition to cardiac tests, it offers arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids, and drugs of abuse. The Evidence MutiStat belongs to a family of flexible and reliable immunoassay analyzers. The largest member of the family is the Evidence, which has an output of 1,400 tests per hour.

The MutiStat system is suitable for emergency departments, cardiac units, doctor's surgeries, forensic units, rehabilitation units, and employee drug screening centers. The technology offers fully automated pipetting, incubation, washing, imaging, and report generation. This, together with a user-friendly touch screen and Windows-based software, enables the MultiStat to be used by nontechnical staff with little or no training.

The test menu can work with a wide range of sample matrix including urine and serum--plasma and whole blood are currently in development. The cardiac arrays include creatinine kinase-MB (CK-MB), fatty acid binding protein (FABP), myoglobin, and cardiac troponin. The drugs of abuse arrays include multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids, and cocaine.

Cardiovascular disease is a progressive and complicated condition, covering a range of symptoms and biochemical processes that vary according to the patient. Multiple markers are therefore required to provide accurate diagnoses. The new Randox technology benefits patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.

Related Links:

Randox



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new study aims to enhance colorectal cancer prevention by identifying polyp molecular signals (Photo courtesy of Shutterstock)

RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous

Colorectal cancer has become a growing health crisis, especially as it increasingly affects younger adults in their 20s, 30s, and 40s, while screening rates remain low. Colorectal cancer is now the leading... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.